Related Experiment Videos
[The effect of cerebrocrast on erythrocyte function]
Insights
The new drug cerebrocrast prevents red blood cell (RBC) deformability issues during and after cerebral ischemia in rats. It also reduces RBC aggregation and oxygen binding, potentially by increasing 2,3-DPG levels.
Area of Science:
- Neuroscience
- Hematology
- Pharmacology
Background:
- Cerebral ischemia can lead to erythrocyte (red blood cell) deformability disturbances.
- These disturbances can worsen blood flow and neurological damage.
- Cerebrocrast is a novel calcium antagonist investigated for neuroprotective effects.
Purpose of the Study:
- To evaluate the effect of cerebrocrast on erythrocyte deformability during and after cerebral ischemia.
- To assess cerebrocrast's impact on erythrocyte aggregation and hemoglobin-oxygen affinity.
Main Methods:
- Cerebral ischemia was induced in rats via carotid artery occlusion for 30 minutes.
- Cerebrocrast was administered intravenously at a dose of 0.4 µg/kg/min for 15 minutes.
- Erythrocyte deformability, aggregation, and hemoglobin-oxygen affinity were measured.
Main Results:
- Cerebrocrast prevented erythrocyte deformability disturbances at the end of ischemia and 1 hour post-reperfusion.
- The drug reduced spontaneous erythrocyte aggregation and the strength of aggregates.
- Cerebrocrast decreased hemoglobin affinity for oxygen, linked to increased erythrocytic 2,3-diphosphoglycerate.
Conclusions:
- Cerebrocrast demonstrates protective effects on erythrocyte function during cerebral ischemia.
- The drug may mitigate ischemia-induced microcirculatory dysfunction.
- Cerebrocrast's mechanism involves modulation of erythrocyte aggregation and oxygen release.
Abstract:
The new calcium antagonist cerebrocrast intravenously infused in a dose of 0.4 micrograms.kg-1.min-1 during 15 min prevented erythrocyte deformability disturbances at the end of cerebral ischemia in rats, which was induced by carotid artery occlusion during 30 min. The agents also prevented the deformability 1 hour after the onset of recirculation. Cerebrocrast reduced spontaneous erythrocyte aggregation, the strength of erythrocytic aggregates, and hemoglobin affinity for oxygen. The latter effect was associated with the drug-induced increase in erythrocytic 2,3-diphosphoglycerate levels.